GB261

BIOLOGICAL2 trials

Sponsors

Genor Biopharma Co., Ltd., Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Conditions

B Cell NHLCLLSystemic Lupus Erythematosus (SLE)

Phase 1

A Safety, Tolerability, Pharmacokinetics and Efficacy Study of GB261 in B-Cell NHL and CLL.

Genor Biopharma Co., Ltd.B Cell NHL, CLL

Start: 2021-08-31End: 2025-06-28Target: 460Updated: 2023-05-22

An Open-label Study of GB261 in Refractory Seropositive Systemic Lupus Erythematosus

Not yet recruitingNCT06945068

Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologySystemic Lupus Erythematosus (SLE)

Start: 2025-06-30End: 2026-11-30Target: 19Updated: 2025-04-25

Related Papers

GB261, an Fc-Function Enabled and CD3 Affinity De-Tuned CD20/CD3 Bispecific Antibody, Demonstrated a Highly Advantageous Safety/Efficacy Balance in an Ongoing First-in-Human Dose-Escalation Study in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Blood2023-11-0212 citations